Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006923 · ClinicalTrials.gov registry record · Phase 2
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
A Phase 2 study, sponsored by Anwaar Saeed.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT06006923: Clinical Trial Phase 2 study, sponsored by Anwaar Saeed.
NCT06006923 is a Phase 2 study that was terminated before completion, run by Anwaar Saeed. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06006923, a Phase 2 study, was terminated before completion, sponsored by Anwaar Saeed.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.
Primary Outcome
Percentage of patients with partial response (PR) or complete response (CR) to the treatment per RECIST 1.1. criteria. v1.1. Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Interventions
- DRUG Pembrolizumab
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-06-26 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 2 |
Why NCT06006923 stopped before completion
NCT06006923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06006923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06006923 about?
NCT06006923 is a clinical study titled "Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer". This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.
What is the current status of trial NCT06006923?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2024-06-26. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT06006923?
The interventions under investigation include: Pembrolizumab (DRUG), Regorafenib (DRUG).
Who is sponsoring clinical trial NCT06006923?
This trial is sponsored by Anwaar Saeed, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06006923's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI